These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34893348)

  • 21. Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review.
    Israel E; Canonica GW; Brusselle G; Yang S; Howarth PH; Martin AL; Koufopoulou M; Smith SG; Alfonso-Cristancho R
    J Asthma; 2022 Nov; 59(11):2201-2217. PubMed ID: 34951336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
    Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
    Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study.
    Enríquez-Rodríguez AI; Hermida Valverde T; Romero Álvarez P; López-González FJ; Gullón Blanco JA; Expósito Villegas AR; Escobar Fernández MJ; Beristáin Urquiza AM; Alonso Fernández MÁ; Gutiérrez Rodríguez M; Castaño De Las Pozas G; Jiménez Pérez J; Fernández Mellado R; García Clemente MM; Casan Clara P
    J Asthma; 2022 May; 59(5):1005-1011. PubMed ID: 33653213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma.
    d'Ancona G; Kavanagh J; Roxas C; Green L; Fernandes M; Thomson L; Dhariwal J; Nanzer AM; Jackson DJ; Kent BD
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32060061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study).
    Martínez-Moragón E; García-Moguel I; Nuevo J; Resler G;
    BMC Pulm Med; 2021 Dec; 21(1):417. PubMed ID: 34922515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics.
    Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
    Clin Exp Allergy; 2020 Apr; 50(4):442-452. PubMed ID: 31943429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of mepolizumab in patients with severe eosinophilic asthma: results from real-world clinical practice in Finland.
    Koistinen V; Kauppi P; Idänpään-Heikkilä J; Veijalainen L; Iso-Mustajärvi I; Ylisaukko-Oja T; Mehtälä J; Viinanen A; Kilpeläinen M
    J Asthma; 2022 Dec; 59(12):2375-2385. PubMed ID: 35094632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies.
    Casale TB; Burnette A; Bourdin A; Howarth P; Hahn B; Stach-Klysh A; Khurana S
    Ther Adv Respir Dis; 2022; 16():17534666221107313. PubMed ID: 35972211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment Eligibility of Real-Life Mepolizumab-Treated Severe Asthma Patients.
    Richards LB; van Bragt JJMH; Aarab R; Longo C; Neerincx AH; Sont JK; Weersink EJM; Braunstahl GJ; Brinke AT; Bel EHD; Maitland-van der Zee AH
    J Allergy Clin Immunol Pract; 2020 Oct; 8(9):2999-3008.e1. PubMed ID: 32344189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy.
    Fyles F; Nuttall A; Joplin H; Burhan H
    J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2715-2723. PubMed ID: 37245734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma: Austrian real-life data.
    Renner A; Marth K; Patocka K; Idzko M; Pohl W
    Pulm Pharmacol Ther; 2020 Oct; 64():101946. PubMed ID: 32949705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
    Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
    Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
    Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
    J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of mepolizumab in elderly patients with severe asthma and overlapping COPD in real-world settings: A retrospective observational study.
    Isoyama S; Ishikawa N; Hamai K; Matsumura M; Kobayashi H; Nomura A; Ueno S; Tanimoto T; Maeda H; Iwamoto H; Hattori N
    Respir Investig; 2021 Jul; 59(4):478-486. PubMed ID: 33849780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry.
    Thomas D; Harvey ES; McDonald VM; Stevens S; Upham JW; Katelaris CH; Kritikos V; Gillman A; Harrington J; Hew M; Bardin P; Peters M; Reynolds PN; Langton D; Baraket M; Bowden JJ; Bowler S; Chien J; Chung LP; Farah CS; Grainge C; Jenkins C; Katsoulotos GP; Lee J; Radhakrishna N; Reddel HK; Rimmer J; Sivakumaran P; Wark PAB; Gibson PG
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2715-2724.e5. PubMed ID: 33545399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia.
    Jesenak M; Vanecek V; Ondrusova M; Urdova V; Dostalova K; Hochmuth L
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Sep; 167(3):272-280. PubMed ID: 37439266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma.
    Pertzov B; Unterman A; Shtraichman O; Shitenberg D; Rosengarten D; Kramer MR
    J Asthma; 2021 Jan; 58(1):79-84. PubMed ID: 31479312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma.
    Pilette C; Canonica GW; Chaudhuri R; Chupp G; Lee FE; Lee JK; Almonacid C; Welte T; Alfonso-Cristancho R; Jakes RW; Maxwell A; Price RG; Howarth P
    J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2646-2656. PubMed ID: 35753668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One year of mepolizumab. Efficacy and safety in real-life in Italy.
    Bagnasco D; Caminati M; Menzella F; Milanese M; Rolla G; Lombardi C; Bucca C; Heffler E; Paoletti G; Testino E; Manfredi A; Caruso C; Guida G; Senna G; Bonavia M; Riccio AM; Canonica GW; Passalacqua G
    Pulm Pharmacol Ther; 2019 Oct; 58():101836. PubMed ID: 31473366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations.
    Akenroye A; Marshall J; Simon AL; Hague C; Costa R; Jamal-Allial A; McMahill-Walraven CN; Haffenreffer K; Han A; Wu AC
    J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1568-1574.e2. PubMed ID: 38431251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.